Biotech Investors & VC Firms in Singapore
85 firms in this list, with a median first check of $826K. 19 of them lead rounds. Generated from verified public data and updated continuously.
CBC Group
SingaporeSeed–Late Stage
2 people
PTV Healthcare Capital
SingaporeSeries B–Late Stage
Capria Ventures
BengaluruSeed–Late Stage$300K – $1M
27 people
Gobi Partners
Hong KongPre-Seed–Late Stage$709K – $37M
74 people
Frazier Life Sciences
Palo AltoSeed–Late Stage
77 people
IMM Investment Japan
SeoulSeed–Late Stage
21 people
Novo Holdings
CopenhagenPre-Seed–Late Stage$1.1M – $54M
47 people
HongShan Capital Group
Hong KongPre-Seed–Late Stage$100K – $50M
46 people
SMBC Venture Capital
TokyoPre-Seed–Late Stage$2.3M – $269M
27 people
Big Idea Ventures
New YorkPre-Seed–Seed$125K – $2.5M
14 people
Artesian
SydneyPre-Seed–Late Stage$20M
39 people
Celesta Capital
Menlo ParkSeed–Late Stage$5M – $20M
33 people
We Ventures
SeoulSeed–Series B$743K – $19M
AgFunder
San FranciscoSeed–Growth$10K – $5M
24 people
Lightstone Ventures
Portola ValleyPre-Seed–Late Stage
32 people
AC Ventures
JakartaSeed–Growth$963K – $87M
30 people
Blume Ventures
MumbaiSeed–Late Stage$650K – $36M
21 people
UntroD Capital
TokyoPre-Seed–Growth$772K – $241M
5 people
UTEC
TokyoPre-Seed–Growth$3.1M – $78M
1 person
HCVC
ParisPre-Seed–Series A$100K – $1M
6 people
Karista
ParisPre-Seed–Late Stage$324K – $5.4M
12 people
SeaX Ventures
MillbraePre-Seed–Series A$100K – $5M
32 people
Trendlines Group
MisgavPre-Seed–Late Stage$650K – $15M
18 people
Series Ventures
ChangwonSeed–Series A$74K – $4.4M
26 people
Related lists
Investors & VC Firms in North America (14143)Investors & VC Firms in United States (13281)Investors & VC Firms in Europe (5575)Crypto & Web3 Investors & VC Firms (4830)Investors & VC Firms in Global (4158)SaaS Investors & VC Firms (3865)AI & Machine Learning Investors & VC Firms (3769)Fintech Investors & VC Firms (3726)Investors & VC Firms in Asia-Pacific (3574)Healthtech Investors & VC Firms (3415)
Data sourced from public filings and firms' own websites — see our methodology.


























































































